SERA PROGNOSTICS, INC.

Sera Prognostics, Inc. (NASDAQ: SERA) is a women's health company that develops and commercializes blood-based biomarker tests and predictive analytics products designed to improve maternal and neonatal health outcomes. The company operates through a proprietary proteomics and bioinformatics platform that analyzes protein expression patterns in maternal blood to predict pregnancy complications and enable early clinical intervention.

The company's flagship product is the PreTRM test, a non-invasive blood test administered during weeks 18-20 of pregnancy that predicts the risk of spontaneous preterm birth before 37 weeks' gestation. The PreTRM test represents the only broadly validated, commercially available blood-based biomarker test for preterm birth prediction. Clinical trials including the PRIME study and AVERT PRETERM TRIAL have demonstrated significant clinical benefits, including a 20% reduction in neonatal intensive care unit admissions, a 20% reduction in neonatal morbidity and mortality, and a 56% reduction in births before 32 weeks among tested populations.

Sera's technology platform consists of proprietary biobanks containing comprehensively annotated blood specimens from thousands of pregnant women across diverse U.S. demographics, advanced mass spectrometry analytical methods, immunoassays, and sophisticated bioinformatics capabilities including machine learning and artificial intelligence applications. The company has validated its biomarker signatures across independent cohorts from the United States, Europe, Asia, and Africa.

Beyond preterm birth, Sera is developing a pipeline of additional blood-based biomarker tests targeting other major pregnancy complications including preeclampsia, gestational diabetes, and fetal growth restriction. The company's commercialization strategy focuses on demonstrating clinical and economic value to healthcare providers, insurance payers, and patients through rigorous clinical evidence and health economic modeling.

Sera has established a commercial collaboration with Elevance Health to expand payment and coverage for the PreTRM test. The company's business model emphasizes evidence-based development, third-party reimbursement, and engagement with professional medical societies to support guideline adoption. The PreTRM test received a unique CPT code priced by CMS at $750 in November 2021. More information is available at www.seradiagnostics.com.